Lipegfilgrastim
- Generic Name
- Lipegfilgrastim
- Brand Names
- Lonquex
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1117844-87-7
- Unique Ingredient Identifier
- 4AWF0N6QV3
- Background
Lipegfilgrastim, previously known as XM22, is a pegylated, recombinant granulocyte colony-stimulating factor (G-CSF) that was synthetized using a highly site-specific glycoPEGylation technology . It is used as an alternate to Pegfilgrastim for prophylactic use in cancer patients receiving chemotherapy and at risk for developing chemotherapy-induced neutropen...
- Indication
Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) .
- Associated Conditions
- Febrile Neutropenia, Neutropenia
- Associated Therapies
- -
Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer
- Conditions
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Beaumont Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02527317
- Locations
- 🇮🇪
Beaumont Hospital, Dublin, Ireland
PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Merckle GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT02306915
- Locations
- 🇬🇧
Teva Investigational Site 34193, London, United Kingdom
A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT02044276
- Locations
- 🇮🇹
Teva Investigational Site 30059, Milano, Italy
🇩🇪Teva Investigational Site 32275, Koeln, Germany
🇩🇪Teva Investigational Site 32284, Aurich, Germany
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Merckle GmbH
- Target Recruit Count
- 21
- Registration Number
- NCT01585649
- Locations
- 🇧🇬
Teva Investigational Site 0103, Plovdiv, Bulgaria
🇧🇬Teva Investigational Site 0102, Varna, Bulgaria
🇺🇦Teva Investigational Site 0704, Kyiv, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.